ONC

Beone Medicines Stock Analysis

AI Rating

Good
  • Quality9/10
  • Growth↑ 6/10
  • Momentum↑ 7/10
Beone Medicines sales and earnings growth
ONC Growth
Good
  • Revenue Y/Y↑ 49.92%
  • EPS Y/Y↑ 107.81%
  • FCF Y/Y↑ 153.47%
Beone Medicines gross and profit margin trends
ONC Profitability
Good
  • Gross margin ↑ 86.20%
  • EPS margin↓ 1.40%
  • ROIC↓ 6.60%
Beone Medicines net debt vs free cash flow
ONC Risk
Great
  • Debt / Equity↓ 0.5
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 8.0

Beone Medicines stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗